Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
Marco Falcone, Giusy Tiseo, Alessandro Leonildi, Leonardo Della Sala, Alessandra Vecchione, Simona Barnini, Alessio Farcomeni, Francesco Menichetti
Abstract
= 0.079). Among 8 cases in the cefiderocol group who experienced microbiological failure, 4 (50%) developed resistance to cefiderocol. Cefiderocol represents a promising therapeutic option in patients with severe CRAB infections. Randomized clinical trial in this specific patient population should confirm our findings.
Topics & Concepts
ColistinAcinetobacter baumanniiMedicineInternal medicineHazard ratioCarbapenemPolymyxinAntibioticsSeptic shockPneumoniaPseudomonas aeruginosaIntensive care medicineConfidence intervalSepsisBiologyMicrobiologyBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance